Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dabrafenib and Trametinib for Ameloblastoma
NCT06653517Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in ameloblastoma, sponsored by Shanghai Ninth People's Hospital. Started Jan 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on NCT06653517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653517.